Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro

被引:22
|
作者
Arul, Melanie [1 ]
Roslani, April Camilla [2 ]
Cheah, Swee Hung [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur 50603, Malaysia
关键词
Colorectal cancer; Fluorouracil; Oxaliplatin; Drug combination; Chou-Talalay; MULTICENTER RANDOMIZED-TRIAL; CIRCULATING TUMOR-CELLS; DOWN-REGULATION; PLATINUM RESISTANCE; 1ST-LINE TREATMENT; REPAIR PATHWAYS; PROSTATE-CANCER; GENE-EXPRESSION; BREAST-CANCER; KAPPA-B;
D O I
10.1007/s11626-016-0126-x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Tumor heterogeneity may give rise to differential responses to chemotherapy drugs. Therefore, unraveling tumor heterogeneity has an implication for biomarker discovery and cancer therapeutics. To test this phenomenon, we investigated the differential responses of three secondary colorectal cancer cell lines of different origins (HCT116, HT29, and SW620 cells) and four novel primary cell lines obtained from different colorectal cancer patients to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) and explored the differences in gene expression among the primary cell lines in response to exposure to cytotoxic drugs. Cells were exposed to different doses of 5-FU and L-OHP separately or in combinations of equitoxic drug or equimolar drug ratios (median effect of Chou-Talalay principle). Cell viability was assessed using MTT assay and the respective IC50 values were determined. Changes in gene expression in primary cell lines after exposure to the same drug doses were compared using real-time PCR array. The sensitivities (IC50) of different cell lines, both secondary and primary, to 5-FU and L-OHP were significantly different, whether in monotherapy or combined treatment. Primary cell lines needed higher doses to reach IC50. There were variations in gene expression among the primary cell lines of different chemosensitivities to the challenge of the same combined dose of 5-FU and L-OHP. The results confirm the heterogeneous nature of colorectal cancer cells from different patient tumors. Studies using primary cancer cells established from patient's tumors rather than secondary cell lines will more closely reflect the actual character of the disease.
引用
收藏
页码:435 / 447
页数:13
相关论文
共 50 条
  • [31] Learning curves for drug response prediction in cancer cell lines
    Partin, Alexander
    Brettin, Thomas
    Evrard, Yvonne A.
    Zhu, Yitan
    Yoo, Hyunseung
    Xia, Fangfang
    Jiang, Songhao
    Clyde, Austin
    Shukla, Maulik
    Fonstein, Michael
    Doroshow, James H.
    Stevens, Rick L.
    BMC BIOINFORMATICS, 2021, 22 (01)
  • [32] Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines
    Khan, Ishaq
    Baeesa, Saleh
    Bangash, Mohammed
    Schulten, Hans-Juergen
    Alghamdi, Fahad
    Qashqari, Hanadi
    Madkhali, Nawal
    Carracedo, Angel
    Saka, Mohamad
    Jamal, Awatif
    Al-Maghrabi, Jaudah
    AlQahtani, Mohammed
    Al-Karim, Saleh
    Damanhouri, Ghazi
    Saini, Kulvinder
    Chaudhary, Adeel
    Abuzenadah, Adel
    Hussein, Deema
    CANCER CELL INTERNATIONAL, 2017, 17
  • [33] Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines
    Ishaq Khan
    Saleh Baeesa
    Mohammed Bangash
    Hans-Juergen Schulten
    Fahad Alghamdi
    Hanadi Qashqari
    Nawal Madkhali
    Angel Carracedo
    Mohamad Saka
    Awatif Jamal
    Jaudah Al-Maghrabi
    Mohammed AlQahtani
    Saleh Al-Karim
    Ghazi Damanhouri
    Kulvinder Saini
    Adeel Chaudhary
    Adel Abuzenadah
    Deema Hussein
    Cancer Cell International, 17
  • [34] Different mechanism of Oxaliplatin resistance in human colorectal cancer cell lines
    Yamano, Tomoki
    Kubo, Shuji
    Yano, Aya
    Tomita, Naohiro
    CANCER RESEARCH, 2015, 75
  • [35] Subcellular proteomics analysis of different stages of colorectal cancer cell lines
    Mathieu, Alex-Ane
    Ohl-Seguy, Emma
    Dubois, Marie-Line
    Jean, Dominique
    Jones, Christine
    Boudreau, Francois
    Boisvert, Francois-Michel
    PROTEOMICS, 2016, 16 (23) : 3009 - 3018
  • [36] Endothelial cell heterogeneity in colorectal cancer: tip cells drive angiogenesis
    Xie, Zhenyu
    Niu, Liaoran
    Du, Kunli
    Chen, Ling
    Zheng, Gaozan
    Dai, Songchen
    Dan, Hanjun
    Duan, Lili
    Dou, Xinyu
    Feng, Fan
    Zhang, Jian
    Zheng, Jianyong
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2024, 81 (01)
  • [37] Proteomic changes in colorectal cancer cell lines in response to sorafenib treatment
    Auer, T.
    Gamerith, G.
    Sarg, B.
    Mueller, D.
    Zwierzina, H.
    Lindner, H.
    Hilbe, W.
    Loeffler-Ragg, J.
    EJC SUPPLEMENTS, 2009, 7 (04): : 34 - 34
  • [38] Heterogeneity of androgen receptor dynamics and drug response in prostate cancer cells
    Patsch, Katherin
    Soundararajan, Anjana
    Engeln, Mark
    Gross, Mitchell E.
    Mumenthaler, Shannon M.
    Ruderman, Daniel
    CANCER RESEARCH, 2017, 77
  • [39] Stem Cell Differentiation and Lumen Formation in Colorectal Cancer Cell Lines and Primary Tumors
    Ashley, Neil
    Yeung, Trevor M.
    Bodmer, Walter F.
    CANCER RESEARCH, 2013, 73 (18) : 5798 - 5809
  • [40] Developing engineered and primary cancer cell lines for oncology drug development
    Hao, Feng
    Zhang, Wenna
    Peng, Hao
    He, Feng
    Bai, Zhaoshuai
    Liu, Changpeng
    Wang, Guoqian
    Xu, Juan
    Qu, Yang
    Ning, Jinying
    CANCER RESEARCH, 2018, 78 (13)